SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-19-023055
Filing Date
2019-06-21
Accepted
2019-06-21 14:02:25
Documents
9
Period of Report
2019-06-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tptx-8k_20190619.htm 8-K 36522
2 EX-10.1 tptx-ex101_7.htm EX-10.1 384792
3 EX-10.2 tptx-ex102_8.htm EX-10.2 24645
4 GRAPHIC ghfpec3u4kp4000002.jpg GRAPHIC 60726
5 GRAPHIC ghfpec3u4kp4000003.jpg GRAPHIC 122624
6 GRAPHIC ghfpec3u4kp4000006.jpg GRAPHIC 27316
7 GRAPHIC ghfpec3u4kp4000005.jpg GRAPHIC 93259
8 GRAPHIC ghfpec3u4kp4000001.jpg GRAPHIC 63563
9 GRAPHIC ghfpec3u4kp4000004.jpg GRAPHIC 105419
  Complete submission text file 0001564590-19-023055.txt   1099472
Mailing Address 10628 SCIENCE CENTER DRIVE, SUITE 225 SAN DIEGO CA 92121
Business Address 10628 SCIENCE CENTER DRIVE, SUITE 225 SAN DIEGO CA 92121 858-926-5251
Turning Point Therapeutics, Inc. (Filer) CIK: 0001595893 (see all company filings)

IRS No.: 463826166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38871 | Film No.: 19911040
SIC: 2834 Pharmaceutical Preparations